The best treatment for avascular necrosis (AVN) depends almost entirely on how far the condition has progressed when it’s caught. In early stages, before the bone surface collapses, joint-preserving procedures like core decompression can succeed in up to 84% of cases. Once the femoral head has collapsed significantly, total hip replacement becomes the most reliable option, with modern implants lasting well beyond a decade in most patients. The key factor is timing: earlier detection opens the door to less invasive treatments with better long-term outcomes.
How Staging Shapes Your Treatment Options
AVN is classified into stages based on how much damage has occurred to the bone, typically the femoral head at the top of your thighbone. The most widely used systems describe stages from 0 through 4 or higher, ranging from suspected disease with no visible changes on imaging all the way to full collapse of the joint surface and arthritis.
In the earliest stages (0 and I), standard X-rays look normal. The disease is only detectable on MRI or bone scans. By Stage II, X-rays start showing cystic and hardened areas inside the bone, but the shape of the femoral head is still intact. Stage III marks the beginning of structural collapse, and Stage IV involves significant joint destruction. Treatment guidelines recommend factoring in the specific stage, the size of the dead bone area, the patient’s age, and how much pain and functional loss they’re experiencing.
Medications That May Slow Progression
Several drug classes have been studied for early-stage AVN, though none are considered a standalone cure. Bisphosphonates, which work by slowing bone breakdown, are the most studied. Patients treated with alendronate (a common bisphosphonate) showed decreased bone marrow swelling on MRI in most cases. These medications are typically paired with calcium and vitamin D supplements.
Blood thinners like enoxaparin have also been tested, based on the theory that tiny blood clots contribute to the bone’s lost blood supply. In clinical studies, patients received injections for about 12 weeks. The logic is straightforward: if clots are choking off circulation to the bone, dissolving them could restore blood flow and allow healing. Other medications that have been explored include statins (which may counteract the fat buildup in bone marrow caused by steroid use) and iloprost, a drug that widens blood vessels. Both have shown some benefit in reducing bone marrow swelling in early-stage disease, but the evidence remains limited.
Medications work best as part of a broader plan rather than as a primary treatment. They’re most useful in very early stages or as a complement to surgical procedures.
Core Decompression: The First-Line Surgical Option
Core decompression is the most common joint-preserving surgery for AVN. A surgeon drills one or more small channels into the femoral head to relieve pressure inside the bone, encourage new blood vessel growth, and allow healthier bone to fill in. It’s a relatively straightforward procedure, and recovery begins quickly.
The results depend heavily on when the surgery happens. A meta-analysis found success rates of 84% for Stage I disease, 63% for Stage II, and just 29% for Stage III. For Stage I specifically, core decompression was statistically superior to nonsurgical management. That steep dropoff in success at later stages is why early diagnosis matters so much.
After core decompression, most patients begin walking with crutches and bearing full weight within the first week. Rehabilitation typically starts immediately with stationary cycling (no resistance), gentle bridging exercises, and gait training. By week two, stretching and progressive strengthening are added. The recovery is relatively quick compared to more invasive procedures.
Adding Bone Marrow Concentrate
Some surgeons inject bone marrow aspirate concentrate (BMAC), which contains stem cells, into the decompression site to try to boost healing. The theory is appealing, but the results have been mixed. One study found that only 25% of hips treated with core decompression plus BMAC had favorable outcomes, while 75% eventually needed hip replacement. The average time before those patients required a replacement was 14 months. Patients with smaller lesions fared better, while the addition of BMAC didn’t seem to help with larger areas of dead bone. When the procedure did work, patients reported good pain relief, joint mobility, and walking ability.
Bone Grafting for Intermediate Stages
When AVN has progressed beyond what core decompression can handle but hasn’t reached the point of needing a full joint replacement, bone grafting is an option. The surgeon removes dead bone and replaces it with healthy bone, often taken from the patient’s own fibula (the smaller bone in the lower leg). The graft acts as structural support to prevent the femoral head from collapsing further.
There are two main types. Vascularized grafts come with their own blood supply still attached, while non-vascularized grafts are simply transplanted bone without connected blood vessels. Studies comparing the two for femoral head AVN consistently favor vascularized grafts on functional outcomes. In one study, 70% of patients with vascularized grafts showed improved hip function scores compared to just 35% with non-vascularized grafts. Collapse rates were also dramatically lower: 14% versus 70% in one comparison.
The tradeoff is that vascularized grafts carry a higher risk of surgical complications. They were nearly six times more likely to require a follow-up surgery for wound problems, graft fracture, or mechanical issues. Clinical guidelines specifically recommend vascularized bone grafting for early Stage III disease where the blood supply has been compromised by arterial problems.
Rotational Osteotomy
This specialized procedure involves cutting and rotating the femoral head so that the damaged area is moved away from the weight-bearing zone and healthier bone takes its place. It’s a technically demanding surgery typically reserved for younger patients who want to delay or avoid hip replacement.
Long-term data shows 59% of patients still had their natural hip at 15 years without needing conversion to a hip replacement. However, when radiological failure (visible worsening on imaging) was included as a failure marker, only 30% were considered successful at 15 years. Two factors predicted worse outcomes: being over 40 years old and having lesions that extended to the lateral edge of the hip socket. For younger patients with well-positioned lesions, osteotomy can buy significant time.
Total Hip Replacement for Advanced Disease
Once the femoral head has collapsed substantially (Stage IV) or pain and disability are severe, total hip arthroplasty is the standard treatment. The damaged joint is replaced with artificial components. While joint replacement is sometimes viewed as a last resort, it’s also the most predictable solution for advanced AVN.
Modern cementless hip implants have a 10-year survival rate of approximately 92.5% in AVN patients. That’s slightly lower than the survival rates seen in patients who get hip replacements for osteoarthritis, partly because AVN patients tend to be younger and more active, which puts more wear on the implant over time. Still, current implant technology has narrowed that gap considerably.
Recovery after hip replacement follows a structured timeline. During the first week, you’ll begin gentle range-of-motion exercises and start walking with a walker or crutches, avoiding bending the hip past 90 degrees. By week two, you’ll progress to active stretching, resistance band work, and strengthening exercises for the muscles around the hip. Most patients transition to walking without assistive devices around week three, focusing on proper heel-to-toe mechanics. The emphasis throughout is on gradually returning to normal activities while protecting the new joint.
Shockwave Therapy as a Noninvasive Option
Extracorporeal shockwave therapy (ESWT) delivers focused pressure waves to the affected area, aiming to stimulate blood vessel growth and bone repair. Each session typically involves around 6,000 shockwave pulses. In clinical studies, most patients experienced noticeable improvement within three to six months after treatment, with follow-up assessments continuing out to two years.
ESWT is most relevant for patients with early-stage AVN who are looking for a completely noninvasive approach or who aren’t good candidates for surgery. It doesn’t require anesthesia or hospital stays, and there’s no recovery period that limits weight bearing. The evidence is promising but still limited compared to surgical options, so it’s generally considered a complementary treatment rather than a primary one.
Choosing the Right Approach by Stage
- Stage I (MRI-only findings): Core decompression offers the best results at this stage, with success rates around 84%. Medications like bisphosphonates and protected weight bearing may also be appropriate.
- Stage II (X-ray changes, no collapse): Core decompression remains the primary surgical option, though success drops to about 63%. Bone grafting may be considered for larger lesions.
- Stage III (early collapse): Vascularized bone grafting or rotational osteotomy are the main joint-preserving options. Core decompression success falls to roughly 29% at this point.
- Stage IV (significant collapse and joint damage): Total hip replacement is the recommended treatment, particularly when pain is severe or hip function is substantially limited. Younger patients with mild symptoms may still be considered for joint-preserving approaches.
Age plays a role at every stage. Patients under 40 generally have better outcomes with joint-preserving procedures and stronger motivation to delay replacement, since they’ll likely outlive even the best implants and may need revision surgery later in life. For patients over 40 with advancing disease, proceeding to hip replacement sooner rather than later often provides the most reliable pain relief and return to function.